RT Book, Section
A1 Klotz, Laurence
A2 Feneley, Mark R.
A2 Payne, Heather A.
SR Print(0)
ID 1152370902
T1 Conservative treatment strategies for localized favourable-risk prostate cancer
T2 Therapeutic Strategies in Prostate Cancer
YR 2018
FD 2018
PB Clinical Publishing
PP New York, NY
SN 9781904392880
LK hemonc.mhmedical.com/content.aspx?aid=1152370902
RD 2021/01/27
AB Prostate  cancer  screening  based  on  prostate  biopsy  for  men  with  levels  of  serum  prostate-specific  antigen  (PSA)  above  an  empirical  level,  or  abnormal  digital  rectal  examination  (DRE),  results  in  diagnosing  many  men  with  prostate  cancer  for  whom  the  disease  does  not  pose  a  threat  to  their  life.  Welch  has  recently  calculated  that  there  are  2.74  million  US  men  aged  50–70  with  a  PSA  >  2.5.  If  all  American  men  in  this  age  group  had  a  PSA  blood  test,  and  a  PSA  >  2.5  is  used  as  an  indication  for  biopsy,  this  means  that  in  the  USA  alone  775000  cases  will  be  diagnosed.  This  is  543  000  more  than  the  232  000  cases  diagnosed  in  2005,  and  25  times  more  than  the  30  350  men  expected  to  die  of  prostate  cancer  per  year  in  the  USA  [1].